Results for the quarter ended 30.06.2026

"‘ Vista Pharmaceuticals Ltd CIN : L24239TG1991PLC012264 Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet, Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585 I I A E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com To, Date: 14.08.2026 BSE Limited, P.J. Towers, Dalal Street, Mumbai - 400001 Dear Sir/Madam, Sub: Outcome of board meeting under regulations 30 read with 33 (3) of SEBI (Listing Obligations and Disclosure requirements) regulations, 2015 Unit: Vista Pharmaceuticals Limited (BE Scrip Code:524711) With reference to the subject cited, this is to inform the Exchange that at the Board meeting of M/s. Vista Pharmaceuticals Limited held on Friday, the 14th day of August, 2026, at 2.30 P.M. at the registered office of the Company, the Company the following were duly considered and approved by the Board: 1. Unaudited Financial results for the quarter ended 30.06.2026 (enclosed). 2. Limited Review Report for the Quarter ended 30.06.2026 (enclosed). The meeting of the Board of Directors commenced at 2.30 P.M.(IST) and concluded at 3.15 P.M. (IST) This is for the information and records of the Exchange, please. Thanking you. Yours faithfully, For Vista Pharmaceuticals Limited Dhananjaya Alli Executive Director (DIN: 00610909) T.S.L.I.C. Industrial Estate, Gopalaip: Village), Narketpalli (Mandal), Nalgonda Dist., Telangana - 508254 Tel : +91 91777 15305 Telefax : 08682-272551 E-mail : admin.nkp@vistapharmaceuticals.com '.\ Vista Pharmaceuticals Ltd L\- J CIN 4239TG1991PLC012264 Plot No. 104, RavindrCao Operative Society, Guttala Bec mpe VisTA eya Hills, Hyderabad - 500 081. Telanga I A. Tel : 040 - 23741585 admin.hyd@vistapharm uticals.com vistapharmaceuticals.com VISTA PHARMACEUTICALS LIMITED CIN: L24239TG1991PLC012264 Statement of Unaudited financial results for the Quarter ended 30.06.2026 (Rs. in Lakhs)| _— Quarter ended Year Ended SN Factitoley June 302026 | March 31,2026 Tune 30205 March 312026 Un Audited Audited Un Audited Audited 1 Hnco a. Revenue from operations - - 15188 b. Other inc 3.99 3.28 0.00 2 Total lncome (a+b) 399 3.28 151.88 3 [Expenses l ba )) C Co hs at n go ef M ia n te Ir ni va el n torC io en ss umed - s = - 149.3S4 5221= l¢) Employee berefits experse 51 19.87 5425 4) Finance costs 3359 5527 1931 ¢) Depreciation and amortization expense 18.82 1872 17.58 1) Other expenses 33,14 656.30 58.90 2) Prior Period Expenses - - Total Expenses 136.70 780.16 299.38 2,186.58 4 |Prone berore tax (2-3) asz7n) (776.88) (148.01) (1,615.13) Tax expense (1) Current tax » = ] (2) Deferred tax (34.12) (190.59) (18.97) -409.01 jous year Income tex adjustment = = = 6 |Net Profit for the Period (4-5) (98.59) (586.29) (129.04) (1206.12)] 7 |Other comprehensive income (OCI) Items that will not be reclassified Subsequently to - 0.62 (293) 1.47 045 profit or loss Tax on items that may not be reclassified to profi _ N N _ or loss Items that will be reclassified to profit or loss: - = = - Total Other Comprehensive income 0.62 (2.93) 147 0.45 8 Total Comprehensive income (6+7) 97.98) (589.22) (127.57) (1,205.67)| g [EAE unSauksaNae cpmi(Face Yalucor 123104 123104 123104 1231.04 10 |Other Equity 1 e ngs per equity share lus of Rs. 10/~ cach) (1.96) (1) Basic (2) Diluted a. Notes: 1.The financial results of the company have been prepared in accordance with Indian Accouting Standards (Ind AS) notified under the companies (Indian Accouting standards) Rules, 2015 as amended by the companies (Indian Accouting standards) (Amendment) rules, 2016. 2. The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 14th August, 2026. 3.The Statutory Auditors of the Company have carried out "Limited Review of the above unaudited financial results and their Report has been Pl laced before the Board at the sad Meeting ' 8 as re qq uired under Reg Bu ! lation 33 of SEBI ( (LODR) ) RegReug: lations, 2015. /SCfiEUT\N T.S.LI.C. Industrial Estate, Gopalaipalli (Village), Narketpalli (Mandal), Nalgonda Dist., Telangana - 508254 Tel: +91 91777 15305 Telefax : 08682-272551 E-mail : admin.nkp@vistapharmaceuticals.com ran Vista Pharmaceuticals Ltd CIN : 124239TG1991PLCO12264 Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet, Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585 E-mail : admin.hyd@vistapharmaceuticals.com &www.vistapharmaceuticals.com 4. The revenue from operations for the current quarter is Nil compared to Rs. 151.88 Lakhs for the corresponding quartofe thre previous year. 5. The Loss before tax for the current quarter is Rs. (132.71) Lakhs compared to a Loss Before tax of Rs. (148.01) Lakhs for the corresponding quarter of the previous year 6. The Profit/(Loss) After tax for the current quarter is Rs. (98.59) Lakhs compared to Rs. (129.04) Lakhs for the corresponding quarter of the previous year. 7.The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made. 8. The results for the quarter ended 30th June 2026 are also available on the Bombay Stock Exchange website, the National Stock Exchange website, and on the Company's website. 9. The Company has issued 10,243,998 Convertible Share Warrants and has received 25% of the upfront subscription amounting to INR 307.50| lakhs as part payment. The balance subscription money shall be received as per the terms of the issue before 15th september 2026 10. The Company has incurred a net loss for the quarter ended 30th June amount to be Rs. (132.71) Lakhs and accordingly the Basic Earnings Per Share (EPS) amounts to X (0.16) per equity share. Although the Company has potential equity shares in the form of convertible instruments / share warrants outstanding during the period, the same are considered anti-dilutive due to the loss and hence have not been considered for the purpose of computing Diluted EPS. Consequently, the Diluted Earnings Per Share is the same as the Basic Earnings Per Share, amountintgo (0.16) por equity share 11. As 3t 30 lune, 2026 the Company has outstanding statutory liabilities which have not been paid as on the quarter end, comprising Tax Deducted at Source (TDS) payable X7.16 lakh pertaining to earlier periods, Employees’ State Insurance payable of X2.44 lakh, ProfessionTaalx payable of 1.93 lakh, Provident fund payable of X33.15 lakh. The delay in payment is primarily on account of managing working capital and the Company intends to clear the aforesaid dues in subsequent periods. There are no disputes pending with the statutory authorities in respect of these dues. 12. During the quarter, the Company's credit facilties were classified as a Non-Performing Asset (NPA) by the lender due to default in debt servicing for over 90 days, resulting in a freeze on all working capital accounts and temporarily constrainitnhge Company’s operational liquidity. 13. The Companiys actively working to completthee identification of its MSME creditors, though few 13. gaps remain in this process. To faciltate accurate identification, we have requested all suppliertso submit self-declaration forms confirming their MSME status. The Company is currently in the process of collecting these declarations from suppliers to enhance accurecy in reporting. 14. The company has incurred a loss of 98.59 Lakhs for the Sixth consecutive year and has negative working cagital. 15. The Company has incurred cash losses during the current quarter for the three Month period ended June 30, 2026. As of that date, the [Company’s current liabilities excead its current assets by 183.32 lakhs and its net worth has been decreasing due to accumulated operational losses. The Company has also experienced defaults in the repayment of principal and interest on its long-term bank borrowings, leading to certain [accounts being classified as Non-Performing Assets (NPAs) by le [Showing first 8,000 characters — download PDF for full document]